Top Markets
Coin of the day
Citius Pharmaceuticals, Inc. Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc.

CTXR
株式のランク #34065
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm... Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
株価
$0.5557
時価総額
$6.21M
変化(1日)
-26.46%
変化(1年)
-58.22%
US
取引 Citius Pharmaceuticals, Inc. (CTXR)

カテゴリー

Citius Pharmaceuticals, Inc.(CTXR)の株式分割履歴
Citius Pharmaceuticals, Inc.株(シンボル:CTXR)は合計で0回の株式分割を実施しました。
最新の株式分割はAug 17, 2026に行われました。
Aug 17, 2026より前に購入されたCTXR株は、現在0CTXR株に相当します。
株式分割一覧
株式分割 分割比率 累積分割比率
提供された日付のデータは十分ではありません。
類似企業または競合他社の株式分割
企業 株式分割の回数 累積分割比率
1 x2
US
0 -
NL
0 -
CH
0 -
KR
0 -
BE